Table 1.
Demographic and clinical characteristics of sample (N = 108)
| All (N = 108) | HIV+ (n = 72) | HIV− (n = 36) | p-value | |
|---|---|---|---|---|
| Descriptive demographics | ||||
| Age, mean (SD) | 58.5 (6.3) | 58.2 (6.5) | 59.0 (5.9) | .53 |
| Education, mean (SD) | 14.5 (2.6) | 14.6 (2.6) | 14.3 (2.7) | .57 |
| Male, n (%) | 83 (76.9%) | 61 (84.7%) | 22 (61.1%) | .006 |
| Non-Hispanic White, n (%) | 84 (77.8%) | 61 (84.7%) | 23 (63.9%) | .01 |
| Vital Signs and Anthropometrics | ||||
| Pulse pressure, mean (SD) | 58.8 (17.8) | 58.8 (17.6) | 58.7 (18.5) | .98 |
| SBP, mean (SD) | 134.4 (20.9) | 133.4 (20.7) | 136.4 (21.7) | .49 |
| DBP, mean (SD) | 75.6 (11.1) | 74.6 (10.0) | 77.7 (12.8) | .17 |
| MAP, mean (SD) | 95.0 (12.5) | 94.0 (11.8) | 97.0 (13.7) | .23 |
| Pulse, mean (SD) | 65.2 (10.9) | 65.5 (11.5) | 64.7 (9.8) | .70 |
| BMI, mean (SD)a | 27.4 (5.7) | 27.5 (5.8) | 27.3 (5.4) | .87 |
| Medical comorbidites | ||||
| Hyperlipidemia, n (%) | 54 (50.0%) | 43 (59.7%) | 11 (30.6%) | .004 |
| Hypertension, n (%) | 45 (41.7%) | 32 (44.4%) | 13 (36.1%) | .41 |
| Ever smoker, n (%) | 45 (41.7%) | 30 (41.7%) | 15 (41.7%) | 1.00 |
| Current smoker, n (%) | 37 (34.3%) | 27 (37.5%) | 10 (27.8%) | .32 |
| Diabetes mellitus, n (%) | 27 (25.0%) | 20 (27.8%) | 7 (19.4%) | .35 |
| Hepatitis C Virus, n (%) | 22 (20.4%) | 16 (22.2%) | 6 (16.7%) | .50 |
| Current Medications | ||||
| NSAID, n (%) | 33 (30.6%) | 25 (34.7%) | 8 (22.2%) | .18 |
| Antihypertensive drug, n (%) | 34 (31.5%) | 26 (36.1%) | 8 (22.2%) | .14 |
| Lipid-lowering drug, n (%) | 40 (37.0%) | 32 (44.4%) | 8 (22.2%) | .02 |
| Antidepressant drug, n (%) | 35 (32.4%) | 32 (44.4%) | 3 (8.3%) | <.001 |
| Psychiatric characteristics/diagnoses | ||||
| Current MDD, n (%)a | 9 (8.4%) | 8 (11.3%) | 1 (2.8%) | .13 |
| LT MDD, n (%) | 50 (46.3%) | 40 (55.6%) | 10 (27.8%) | .006 |
| LT alcohol use disorder, n (%) | 52 (48.6%) | 36 (50.0%) | 16 (45.7%) | .68 |
| LT cannabis use disorder, n (%) | 30 (28.0%) | 23 (31.9%) | 7 (20.0%) | .20 |
| LT meth use disorder n (%) | 29 (27.1%) | 21 (29.2%) | 8 (22.9%) | .49 |
| LT cocaine use disorder, n (%) | 23 (21.5%) | 17 (23.6%) | 6 (17.1%) | .44 |
| MOS physical health, mean (SD) | 70.3 (22.7) | 65.2 (23.2) | 80.3 (18.1) | <.001 |
| MOS mental health, mean (SD) | 70.7 (23.1) | 65.2 (22.9) | 81.7 (19.5) | <.001 |
| Biomarkers of vascular injury and remodeling | ||||
| Ang-2 (pg/mL), median [IQR] | 4073 [2865, 5359] | 4030 [3002, 5443] | 4144 [2110, 5427] | .48 |
| Tie-2 (pg/mL), median [IQR] | 7307 [6088, 8484] | 7568 [6184, 8386] | 7041 [5540, 8529] | .27 |
| VEGF (pg/mL), median [IQR] | 115 [80, 178] | 126 [87, 206] | 107 [73, 159] | .18 |
Note: Ang-2 = angiopoietin-2; BMI = body mass index; DBP = diastolic blood pressure; LT = lifetime; MAP = mean arterial pressure; MDD = major depressive disorder; meth = methamphetamine; MOS = Medical Outcome Study; NSAID = nonsteroidal anti-inflammatory drug; SBP = systolic blood pressure; Tie-2 = endothelium-specific receptor tyrosine kinase; VEGF = vascular endothelial growth factor
a
n = 107